Endurance Wealth Management, Inc. Cel Sci Corp Transaction History

Endurance Wealth Management, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Oct 28, 2021	SELL	$7.64 - $12.49 $0 - $0	0 Closed	0 $0
Q2 2021 Aug 04, 2021	SELL	$8.68 - $27.49 $251,720 - $797,210	-29,000 Closed	0 $0
Q1 2021 May 05, 2021	BUY	$12.0 - $27.64 $36,000 - $82,920	3,000 Added 11.54%	29,000 $441,000
Q4 2020 Jan 15, 2021	BUY	$11.05 - $16.62 $44,200 - $66,480	4,000 Added 18.18%	26,000 $303,000
Q3 2020 Oct 27, 2020	BUY	$11.69 - $14.54 $128,590 - $159,940	11,000 Added 100.0%	22,000 $281,000
Q1 2020 May 11, 2020	SELL	$7.54 - $17.05 $67,860 - $153,450	-9,000 Reduced 45.0%	11,000 $127,000
Q4 2019 Jan 14, 2020	BUY	$6.71 - $9.55 $46,970 - $66,850	7,000 Added 53.85%	20,000 $183,000
Q3 2019 Oct 18, 2019	BUY	$6.0 - $9.6 $57,000 - $91,200	9,500 Added 271.43%	13,000 $116,000
Q2 2019 Jul 30, 2019	BUY	$3.77 - $8.67 $13,195 - $30,345	3,500 New	3,500 $29,000

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $24.3M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Endurance Wealth Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Endurance Wealth Management, Inc. with notifications on news.